Search results
Advancements in Biologic Therapies for Psoriatic Arthritis
Medscape· 3 days agoThe latest developments in biological therapies for psoriatic arthritis (PsA) are reviewed by Dr...
Alvotech (NYSE:ALVO) Releases Quarterly Earnings Results, Misses Estimates By $0.81 EPS
ETF DAILY NEWS· 6 hours agoAlvotech (NYSE:ALVO – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates ...
6 Signs of an Autoimmune Disease That Can Be Easy to Miss
Self via Yahoo News· 7 days agoA few other notable autoimmune conditions that can cause joint issues? Lupus (one type that attacks...
Low stress resilience is linked to increased risk of psoriasis
Medical Xpress· 3 days agoAs part of the enlistment process, all the men underwent psychological assessment in accordance with...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 4 days ago“We are proud to make SIMLANDI available in the U.S. to patients and providers,” said ...
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena via Yahoo Finance· 3 days ago-inhibiting monoclonal antibody. It was first approved as a treatment for moderate to severe plaque...
What To Know and Do About Arthritis Pain
Health via Yahoo News· 6 days agoArthritis is a condition that causes pain, stiffness, and inflammation in your joints. Fortunately, medications and home remedies can help relieve pain.
Potential Precursor Lesion to Adrenal Tumors Identified
Medscape· 1 day agoCortisol-producing adenomas (CPAs) are preceded by the development of steroids-producing nodules...
Maintenance Tx With Guselkumab for UC Meets All Endpoints
Medscape· 2 days agoGuselkumab (Tremfya, Janssen/Johnson & Johnson) was superior to placebo for maintenance therapy in...
Allegheny Financial Group LTD Increases Holdings in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 4 days agoAllegheny Financial Group LTD boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.3% during the fourth quarter, according to the company in its most recent Form ...